Evolving knowledge and therapy of inflammatory bowel disease

Joshua R. Korzenik, Daniel K. Podolsky

Research output: Contribution to journalReview articlepeer-review

158 Scopus citations


With recent advances in the understanding of its pathophysiology, inflammatory bowel disease has become a very active area for the development of novel therapeutic agents. New targets for biologics include cytokines involved in T-cell activation, with antibodies directed against IL-12 and interferon-γ. Selective adhesion molecule blockade has produced promising, though mixed, results. Recombinant human granulocyte-macrophage colony-stimulating factor might be effective in active Crohn's disease, presumably through stimulation of intestinal innate immune responses. With increasing evidence for a crucial role for luminal flora in maintaining the health of the bowel, strategies to manipulate intestinal bacteria using probiotics and prebiotics are being actively investigated as well.

Original languageEnglish (US)
Pages (from-to)197-209
Number of pages13
JournalNature Reviews Drug Discovery
Issue number3
StatePublished - Mar 2006

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Evolving knowledge and therapy of inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this